Dr. Kouros Motamed is an experienced cancer researcher with proven record of success in directing scientific productivity of multi-disciplinary research teams in academic and industry settings. Dr. Motamed held an Assistant Professor position in the Vascular Biology Center & Dept. of Pathology at Georgia Regents University from 2002 to 2007, where he established novel in vitro co-culture systems of ovarian cancer cells, primary mesothelial cells and macrophages, to test the inhibitory function of extracellular matrix proteins and small molecules. He also initiated and managed multi-disciplinary in-house and outside collaborations to evaluate the role of extracellular matrix proteins in mouse models of Hypertension (DOCA salt and Angiotensin II), Diabetes (STZ, ob/ob), Flow-induced Vascular Remodeling, and Stroke (transient middle cerebral artery occlusion, MCAO). Dr. Motamed also studied mouse models of early and late stage ovarian and prostate cancer to study the molecular signaling of tumor growth and metastasis. After his term in Georgia Health Sciences University, Dr. Motamed was appointed as a Group Head at Abraxis BioScience, where he headed the Molecular Biology & MOA Group researching generation and evaluation of novel in-house and licensed drug delivery systems with particular emphasis on design and execution of Abraxane MOA studies for FDA filings. Other responsibilities included establishment and validation of IHC clinical biomarkers in support of FDA filings. In 2012, he joined Biomiga Diagnostics (A Start-Up Personalized Medicine Diagnostics Company) as the Chief Technical Officer where he directed assay design, sales and marketing of Point-of-Care, Therapeutic Drug Monitoring (TDM) medical tests, and formulated long-term visions and strategies for personalized medicine product lines. Then he joined IGDRASOL, Inc. (A Start-Up Personalized Nanomedicine Therapeutic Company), as Chief Scientific Officer developing two licensed, Phase 3-ready nanoparticle paclitaxel formulations towards US FDA approval. Following acquisition of IGDRASOL, Inc. by Sorrento Therapeutics, Inc., Dr. Motamed was appointed as VP of Clinical Development & Nanomedicine. He currently serves as the VP of Strategic Alliances & Clinical Communications. Dr. Kouros Motamed has over 30 peer-reviewed publications in high impact journals, as well as over 40 published abstracts and 5 patents/patent applications.

The research interests of Dr. Kouros Motamed include: Drug Discovery/Development Angiogenesis/Tumorigenesis/Tumor Microenvironment Normalization Clinical Biomarker/Companion Diagnostic Development Point-of-Care Diagnostics Clinical Development of Personalized Nanomedicines in Solid Tumors